XML 63 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Operating activities:      
Net loss $ (26,624) $ (22,264) $ (35,750)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 569 660 646
Amortization of premium / discount on marketable securities 912 889 1,576
Stock-based compensation 6,146 5,338 8,081
Net loss on disposal of property and equipment   123  
Change in fair value of contingent consideration liability 60    
Net changes in operating assets and liabilities:      
Restricted cash (320)    
Escrow liability 275    
Interest receivable (148) 141 6
Accounts receivable 1,008 (3,414) (553)
Prepaid expenses and other assets (160) 14 (13)
Accounts payable and accrued liabilities 269 (1,503) (139)
Accrued compensation and employee benefits 721 800 315
Deferred revenue (2,190) 11,134 (64)
Net cash used in operating activities (19,482) (8,082) (25,895)
Investing activities:      
Purchases of marketable securities (118,894) (91,428) (112,974)
Maturities of marketable securities 51,129 103,470 83,412
Proceeds from sales of marketable securities     10,139
Acquistion of Ceregene, Inc., net of cash received 79    
Purchases of property and equipment (432) (723) (576)
Net cash provided by / (used in) investing activities (68,118) 11,319 (19,999)
Financing activities:      
Proceeds from public offering of common stock, net of issuance costs 69,492   50,152
Taxes paid related to net share settlement of equity awards (2,015)   (48)
Proceeds from issuance of common stock 8,630 1,676 1,772
Net cash provided by financing activities 76,107 1,676 51,876
Net increase / (decrease) in cash and cash equivalents (11,493) 4,913 5,982
Cash and cash equivalents, beginning of period 21,679 16,766 10,784
Cash and cash equivalents, end of period 10,186 21,679 16,766
Supplemental disclosures of noncash investing activities:      
Fair value of shares of common stock issued pursuant to the acquisition of Ceregene Inc. $ 1,200